Maze Therapeutics, Inc. (MAZE)
25.81
+0.06
(+0.23%)
USD |
NASDAQ |
May 22, 14:07
Maze Therapeutics Cash from Investing (Quarterly) : 6.275M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| LENZ Therapeutics, Inc. | 33.16M |
| CDT Equity, Inc. | 0.595M |
| Liminatus Pharma, Inc. | 0.00 |
| Oruka Therapeutics, Inc. | -14.44M |
| MapLight Therapeutics, Inc. | 67.01M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -39.11M |
| Cash from Financing (Quarterly) | 42.36M |
| Free Cash Flow | -122.12M |
| Free Cash Flow Per Share (Quarterly) | -0.7274 |
| Free Cash Flow to Equity (Quarterly) | -77.12M |
| Free Cash Flow to Firm (Quarterly) | -38.34M |
| Free Cash Flow Yield | -9.70% |